Authors: C Pike H G Birnbaum M Schiller E Swallow R T Burge E T Edgell
Publish Date: 2010/05/20
Volume: 22, Issue: 1, Pages: 47-56
Abstract
This study assesses the costs of nonvertebral osteoporosisrelated fractures patients compared with osteoporosis patients without fractures focusing on the second year following a fracture Since fracture patients remained more costly in the second year their economic burden extends beyond the year in which the fracture occursThe purpose of this study is to examine the comorbidity profile resource use and direct costs of patients who incur osteoporosisrelated nonvertebral NV fractures in the United States during the 2 years following an incident fracture focusing on the second year following a fractureOsteoporosis patients ICD9CM 7330 with a NV fracture hip femur pelvis lower leg upper arm forearm rib and multiple sites were selected from a privately insured health insurance claims database 8 million lives ages 18–64 1999–2006 These NV fracture patients were randomly matched 11 on age gender employment status and geographic region to controls with osteoporosis but without a fracture history Yearbyyear and monthbymonth rates of comorbidities resource use and direct costs were calculated for the matched sample N = 3781Comorbidity rates and resource use remained significantly higher among NV fracture patients during second year following an NV fracture compared with controls although absolute rates of comorbidities and service utilization declined Mean direct excess costs for NV fracture patients fell from 5267 in the first year to 2072 in the second year after a fracture but remained statistically significant p 001 Patients with fractures of the pelvis hip and femur had the highest excess costs in the second year 5121 3930 and 3828 respectively Although hip fractures had highest excess costs over both years nonvertebral nonhip fracture patients made up a larger proportion of the sample and were significantly more costly than controlsThis research project was funded by Eli Lilly and Company Drs Russel Burge and Eric Edgell are employees of Eli Lilly and Company in the Global Health Outcomes department Eli Lilly and Company markets pharmacological therapies for the prevention and treatment of osteoporosis
Keywords: